Oral CBD shows potential systemic anti-inflammatory effects by modulating immune responses and reducing markers like cytokines. Clinical research in humans is expanding to validate these properties across inflammatory disorders.
In patients with HIV, oral CBD was linked to anti-inflammatory gene expression changes in myeloid cells (Marini et al., 2024). A pilot trial in ulcerative colitis found CBD-rich extract improved disease severity and quality-of-life measures (Irving et al., 2018).
Further randomized trials in healthy adults reported reduced pain progression with hemp-derived oral CBD, suggesting broader anti-inflammatory utility (Mastrofini et al., 2024). These results indicate oral CBD's value for managing systemic inflammation.
References
-
Marini, S., et al. (2024). Oral cannabidiol treatment is associated with an anti-inflammatory gene expression signature in myeloid cells of people living with HIV. Cannabis and Cannabinoid Research, 9(4), 1028–1037. https://doi.org/10.1089/can.2023.0139
-
Irving, P. M., Iqbal, T., Prasad, N., Smith, S., Wilks, M., & Higuchi, L. (2018). A randomized, double-blind, placebo-controlled, parallel-group, pilot study of cannabidiol-rich botanical extract in the symptomatic treatment of ulcerative colitis. Inflammatory Bowel Diseases, 24(4), 714–724. https://doi.org/10.1093/ibd/izy002
-
Mastrofini, G. F., et al. (2024). The effects of a brand-specific, hemp-derived cannabidiol product on physiological, biochemical, and psychometric outcomes in healthy adults: A double-blind, randomized clinical trial. Journal of the International Society of Sports Nutrition, 21(1), Article 2370430. https://doi.org/10.1080/15502783.2024.2370430
